OOIR: Observatory of International Research

Papers

(The median citation count of British Journal of Dermatology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*	329
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*	261
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*	214
Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial	194
The global burden of chronic urticaria for the patient and society*	188
Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases	185
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases	170
Exploring the human hair follicle microbiome*	71
British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020*	68
Applications and future directions for optical coherence tomography in dermatology*	63
A narrative review of the epidemiology and economics of chronic wounds	63
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURF	62
Putting the burden of skin diseases on the global map	62
Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings	60
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III,	57
British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021*	57
British Association of Dermatologists guidelines for the management of people with vitiligo 2021	57
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*	54
Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*	53
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial*	52
Challenges in the diagnosis and management of wound infection	51
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial	51
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studi	50
The biological basis of disease recurrence in psoriasis: a historical perspective and current models	50
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*	49

Prevalence, pathophysiology and management of itch in epidermolysis bullosa*	48
Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials	48
Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*	47
Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*	47
Treatment of early‐stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study*	46
Activity and components of the granulocyte colony‐stimulating factor pathway in hidradenitis suppurativa*	45
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclos	45
Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis*	45
The epidemiology of alopecia areata: a population‐based cohort study in UK primary care*	44
A systematic review and network meta-analysis of topical pharmacological, oral pharmacological, physical and combined treatments for acne vulgaris	44
Diagnostic value of cutaneous manifestation of SARS‐CoV‐2 infection*	43
Magnitude and temporal trend of acne vulgaris burden in 204 countries and territories from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019*	43
Tape strips in dermatology research*	42
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study*	41
Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial	39
Ultraviolet A radiation and COVID‐19 deaths in the USA with replication studies in England and Italy*	39
Cutaneous immune‐related adverse events in patients with melanoma treated with checkpoint inhibitors	38
WNT10A , dermatology and dentistry	38
The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb	38
International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut‐off values for defining mild, moderate and severe types of bullous pemphigoid*	38
The associated burden of mental health conditions in alopecia areata: a population‐based study in UK primary care*	37
Body dysmorphia in common skin diseases: results of an observational, cross‐sectional multicentre study among dermatological outpatients in 17 European countries*	37
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials	37
Therapeutic potential of targeting interleukin‐1 family cytokines in chronic inflammatory skin diseases*	37
Cellulitis in chronic oedema of the lower leg: an international cross‐sectional study	36
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study	36
Clinical, dermoscopic and histopathological findings in localized human monkeypox: a case from northern Italy	36
Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1)	36
The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*	36
Alcohol consumption and smoking in relation to psoriasis: a Mendelian randomization study	35
Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*	35
COVID‐19‐related dermatosis in November 2019: could this case be Italy’s patient zero?	34
Association between atopic dermatitis and autoimmune diseases: a population‐based case–control study*	34
Equity in skin typing: why it is time to replace the Fitzpatrick scale	34
Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up	34
Prevalence and incidence of generalized pustular psoriasis in Sweden: a population‐based register study*	34
Enhancement of stratum corneum lipid structure improves skin barrier function and protects against irritation in adults with dry, eczema‐prone skin*	34
Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single‐centre, prospective 1‐year observational cohort study of the first 100 patients treated	33
The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five ye	33
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials	33
The global incidence of bullous pemphigoid: a systematic review and meta‐analysis	33
Dupilumab‐induced phenotype switch from atopic dermatitis to psoriasis is characterized byde novointerleukin‐17A expression: a case report	32
Biomarkers of disease progression in people with psoriasis: a scoping review	32
Early melanoma invasivity correlates with gut fungal and bacterial profiles	31
The effect of screening on melanoma incidence and biopsy rates	31
Interleukin‐17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum	31
Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre st	31
Bullous pemphigoid after SARS‐CoV‐2 vaccination: spike‐protein‐directed immunofluorescence confocal microscopy and T‐cell‐receptor studies	31
Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease	30
Melanoma pathology: new approaches and classification*	30

The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database*	30
British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021*	30
Signalling of multiple interleukin (IL)‐17 family cytokines via IL‐17 receptor A drives psoriasis‐related inflammatory pathways	29
Opsin 5 is a key regulator of ultraviolet radiation‐induced melanogenesis in human epidermal melanocytes*	29
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study	28
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis	27
Minimal, superficial DNA damage in human skin from filtered far‐ultraviolet C	27
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*	27
Topical preparations for the treatment of mild‐to‐moderate acne vulgaris: systematic review and network meta‐analysis*	27
Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study	26
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids:	26
Supportive care in the acute phase of Stevens–Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi‐based consensus	26
Occupational dermatoses during the COVID‐19 pandemic: a multicentre audit in the UK and Ireland	26
SARS‐CoV‐2 spike protein positivity in pityriasis rosea‐like and urticaria‐like rashes of COVID‐19	26
Air pollution‐induced tanning of human skin*	25
Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers	25
Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series	25
Peroxisome proliferator-activated receptor-γ signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial–mesenchymal transition	25
Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial	25
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study	25
A clinical and biological review of keratoacanthoma*	25
Pernio after COVID‐19 vaccination	25
Atopic eczema and obesity: a population‐based study*	25
Hailey–Hailey disease treated with dupilumab: a case series	25
Total body photography for the diagnosis of cutaneous melanoma in adults: a systematic review and meta‐analysis*	25
The Eumelanin Human Skin Colour Scale: a proof‐of‐concept study	24
Are patients benefiting from participation in the German skin cancer screening programme? A large cohort study based on administrative data	24
Evidence of gene–gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins	24
Randomized controlled trial of topical corticosteroid and home‐based narrowband ultraviolet B for active and limited vitiligo: results of the HI‐Light Vitiligo Trial*	24
Association of sex and systemic therapy treatment outcomes in psoriasis: a two‐country, multicentre, prospective, noninterventional registry study*	24
Oral vesiculobullous lesions as an early sign of COVID‐19: immunohistochemical detection of SARS‐CoV‐2 spike protein	24
Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherap	24
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial	24
Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma*	24
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)	24
Association between air pollution and atopic dermatitis in Guangzhou, China: modification by age and season*	24
A guideline for the clinical management of basal cell naevus syndrome (Gorlin–Goltz syndrome)*	24
Relationship between atopic dermatitis, depression and anxiety: a two‐sample Mendelian randomization study	24
Insights into male androgenetic alopecia using comparative transcriptome profiling: hypoxia-inducible factor-1 and Wnt/β-catenin signalling pathways	23
Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial	23
A decade of next‐generation sequencing in genodermatoses: the impact on gene discovery and clinical diagnostics*	23
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials	23
The long noncoding RNA MALAT1 suppresses miR‐211 to confer protection from ultraviolet‐mediated DNA damage in vitiligo epidermis by upregulating sirtuin 1*	23
British Association of Dermatologists guidelines for the management of people with rosacea 2021*	23
New insights in hidradenitis suppurativa from a population‐based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities*	22
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermato	22
Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis	22
Risk of skin cancer in new users of thiazides and thiazide‐like diuretics: a cohort study using an active comparator group*	22
A novel personalized treatment approach for psoriasis: anti‐vascular endothelial growth factor‐A (VEGF‐A) therapy	22
A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*	22
Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity*	22
Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population‐based cohort study*	22
Aetiology of tinea capitis in China: a multicentre prospective study	22
Ca ²⁺ signalling is critical for autoantibody‐induced blistering of human epidermis in pemphigus*	21
A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI‐Relevant and Skindex‐16*	21
Pityriasis rosea‐like eruption after Pfizer–BioNTech COVID‐19 vaccination	21
Large‐scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa*	21
Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*	21
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab	21
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*	21
Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils	21
Association between atopic dermatitis and hypertension: a systematic review and meta‐analysis*	21
Inflammatory skin diseases and wounds	21
Clinical, histopathological and prognostic features of primary cutaneous acral CD8 ⁺ T‐cell lymphoma and other dermal CD8	20
HSP90 inhibitor RGRN‐305 for oral treatment of plaque‐type psoriasis: efficacy, safety and biomarker results in an open‐label proof‐of‐concept study*	20
Silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy to prevent hospital‐acquired pressure ulcers: a pragmatic noncommercial multicentre randomized open‐label parallel‐group me	20
Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients	20
Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis	20
Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*	20
Accuracy of commercially available smartphone applications for the detection of melanoma	20
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study	20
Views on mobile health apps for skin cancer screening in the general population: an in‐depth qualitative exploration of perceived barriers and facilitators*	20
Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data*	20
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): a clinical outcome measure for the severity of atopic dermatitis	20
British Association of Dermatologists guidelines for the management of people with cutaneous lupus erythematosus 2021	20
Chilblain lesions after COVID‐19 mRNA vaccine	19
Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort	19
Keratinocytes and immune cells in the epidermis are key drivers of inflammation in hidradenitis suppurativa providing a rationale for novel topical therapies	19
A monkeypox virus infection mimicking primary syphilis	19
Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity*	19

Patients with psoriasis have a dysbiotic taxonomic and functional gut microbiota*	19
Hidradenitis Suppurativa Area and Severity Index Revised (HASI‐R): psychometric property assessment*	19
The challenges of clinical trials in rare diseases	19
Occupational dermatology in the time of the COVID‐19 pandemic: a report of experience from London and Manchester, UK	19
Epidemiology of prurigo nodularis in England: a retrospective database analysis	19
The impact of the COVID‐19 pandemic on skin cancer incidence and treatment in England, 2020	19
Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult‐to‐treat population	19
Clinical photography in skin of colour: tips and best practices	19
Mortality and clinical response of patients with bullous pemphigoid treated with rituximab	19
Primary cutaneous anaplastic large‐cell lymphoma with marked spontaneous regression of organ manifestation after SARS‐CoV‐2 vaccination	19
Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy*	19
Biomarkers of systemic treatment response in people with psoriasis: a scoping review	19
Chronic prurigo	19
The impact of hidradenitis suppurativa on professional life	19
Inflammatory skin diseases and the risk of chronic kidney disease: population‐based case–control and cohort analyses*	19
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study	18
Development of a condition‐specific patient‐reported outcome measure for measuring symptoms and appearance in vascular malformations: the OVAMA questionnaire	18
Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000–2014 in 59 countries (CONCORD-3)	18
Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)	18
Dupilumab‐associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia ‐specific IgE : a multicentre,	18
Low‐dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome	18
Limited impact of COVID ‐19‐related diagnostic delay on cutaneous melanoma and squamous cell carcinoma tumour characteristics: a nationwide pathology registry analys	18
Incidence of mycosis fungoides and Sézary syndrome in the Netherlands between 2000 and 2020	17
Incidence and trends of basal cell carcinoma in Sweden: a population‐based registry study*	17
Autophagy induction regulates aquaporin 3‐mediated skin fibroblast ageing*	17
Clinical and immunological findings in 55 patients with anti‐laminin 332‐type mucous membrane pemphigoid	17
Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study*	17
Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review*	17
COVID‐19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision	17
Validation of four cutaneous squamous cell carcinoma staging systems using nationwide data*	17
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti‐tumour necrosis factor alpha	17
Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG)*	17
The promise and challenges of cell therapy for psoriasis*	17
Incomplete surgical excision of keratinocyte skin cancers: a systematic review and meta‐analysis*	17
Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology	17
Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app	17
Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome*	17
A nationwide study of the incidence and trends of first and multiple basal cell carcinomas in the Netherlands and prediction of future incidence*	16
Global Guidelines in Dermatology Mapping Project (GUIDEMAP), a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based	16
Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy	16
Enhanced expression of angiotensin‐converting enzyme 2 in psoriatic skin and its upregulation in keratinocytes by interferon‐γ: implication of inflammatory milieu in skin tropism of SARS‐CoV‐2	16
Wound healing: potential therapeutic options	16
Incidence of acute complications of herpes zoster among immunocompetent adults in England: a matched cohort study using routine health data*	16
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials	16
Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis	16
Cemiplimab‐rwlc in advanced cutaneous squamous cell carcinoma: real‐world experience in a French dermatology department	16
Experiences of resuming life after immunotherapy and associated survivorship care needs: a qualitative study among patients with metastatic melanoma	16
Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI)*	16
Melanoma genomics: a state‐of‐the‐art review of practical clinical applications*	15
Why we should abandon the misused descriptor ‘erythema’	15
MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies	15
Trends in keratinocyte skin cancer incidence, mortality and burden of disease in 33 countries between 1990 and 2017	15
COVID‐19‐associated cutaneous manifestations: does human herpesvirus 6 play an aetiological role?	15
Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a scoping review of dermatology clinical practice guidelines*	15
Real‐world experience of off‐label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna	15
Blistering severe cutaneous adverse reactions in children: proposal for paediatric‐focused clinical criteria	15
Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study	15
Perceived psychological stress and risk of herpes zoster: a nationwide population‐based cohort study*	15
A randomized controlled feasibility trial of online compassion‐focused self‐help for psoriasis*	15
Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin	15
Lesional activation of T _c 17 cells in Behçet disease and psoriasis supports HLA class I‐mediated autoimmune responses*	15
Identification of clonal skin myeloid cells by next‐generation sequencing in myelodysplasia cutis	15
Malignancy risk in patients with atopic dermatitis: a population-based cohort study	15
Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib	15
Association between hospital‐diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood*	15
Host traits, lifestyle and environment are associated with human skin bacteria	15
Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate‐to‐severe atopic dermatitis*	15
Predicting sentinel node positivity in patients with melanoma: external validation of a risk‐prediction calculator (the Melanoma Institute Australia nomogram) using a large European population‐based p	15
Flow cytometry for the assessment of blood tumour burden in cutaneous T‐cell lymphoma: towards a standardized approach	15
17th Medical Dermatology Meeting, 13 January 2022	15
Cost‐effectiveness of a policy‐based intervention to reduce melanoma and other skin cancers associated with indoor tanning*	14
Skin ageing and topical rejuvenation strategies	14
Topical steroid withdrawal syndrome: time to bridge the gap	14
Not all melanomas are created equal: a review and call for more research into nodular melanoma	14
Modelling trajectories of parentally reported and physician‐confirmed atopic dermatitis in a birth cohort study*	14
SARS‐CoV‐2 infection in patients with atopic dermatitis: a cross‐sectional study	14
The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation*	14
SARS‐CoV‐2 has not been detected directly by electron microscopy in the endothelium of chilblain lesions	14
Do we need to rethink the diagnoses melanoma in situ and severely dysplastic naevus?	14
Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa*	14
Allergic contact dermatitis caused by dipropylene glycol diacrylate in the Omnipod® insulin pump*	14
British Association of Dermatologists guidelines for the management of adults with delusional infestation 2022	14
Effect of dermatological consultation on survival in patients with checkpoint inhibitor‐associated cutaneous toxicity	14
	14
A multicentre study of naevus‐associated melanoma vs. de novo melanoma, tumour thickness and body site differences*	14
Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial	14
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study	14
British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022	13
Trends in incidence, treatment and survival of Merkel cell carcinoma in England 2004–2018: a cohort study	13
The importance of assessing blood tumour burden in cutaneous T‐cell lymphoma*	13
Validation of an Oral Disease Severity Score for use in oral lichen planus	13
Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds*	13
Living with vulval lichen sclerosus: a qualitative interview study	13
‘Get Data Out’ Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013–2019 in England	13
Evaluating risk of bullous pemphigoid after mRNA COVID ‐19 vaccination	13